This study investigated the safety, clinical activity and patient-reported outcomes of patients with diffuse-type tenosynovial giant-cell tumour (dTGCT) of the soft tissue who were treated with emactuzumab, a humanised anti-colony stimulating factor 1 receptor (CSF-1R) monoclonal antibody and were followed up for up to 2 years after the start of treatment.

Click the button below to download the press release or publication.